Obesity - an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Obesity - an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential. / Torekov, S S; Madsbad, S; Holst, Jens Juul.
I: Obesity Reviews, Bind 12, Nr. 8, 2011, s. 593-601.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Obesity - an indication for GLP-1 treatment?
T2 - Obesity pathophysiology and GLP-1 treatment potential
AU - Torekov, S S
AU - Madsbad, S
AU - Holst, Jens Juul
N1 - © 2011 The Authors. obesity reviews © 2011 International Association for the Study of Obesity.
PY - 2011
Y1 - 2011
N2 - Obesity is common and associated with a high rate of morbidity and mortality; therefore, treatment is of great interest. At present, bariatric surgery is the only truly successful treatment of severe obesity. Mimicking one of the effects of bariatric surgery, namely the increased secretion of glucagon-like peptide (GLP)-1, by artificially increasing the levels of GLP-1 might prove successful as obesity treatment. Recent studies have shown that GLP-1 is a physiological regulator of appetite and food intake. The effect on food intake and satiety is preserved in obese subjects and GLP-1 may therefore have a therapeutic potential. The GLP-1 analogues result in a moderate average weight loss, which is clinically relevant in relation to reducing the risk of type 2 diabetes and cardiovascular disease. Inspired by the hormone profile after gastric bypass, a future strategy in obesity drug development could be to combine several hormones, and thereby produce a superior appetite suppressing hormone profile that may result in a weight loss exceeding that seen in single-agent trials. In conclusion, with the GLP-1 analogues combining a moderate weight loss with beneficial effects on metabolic and cardiovascular risk factors, it seems that we are on the right track for future treatment of obesity.
AB - Obesity is common and associated with a high rate of morbidity and mortality; therefore, treatment is of great interest. At present, bariatric surgery is the only truly successful treatment of severe obesity. Mimicking one of the effects of bariatric surgery, namely the increased secretion of glucagon-like peptide (GLP)-1, by artificially increasing the levels of GLP-1 might prove successful as obesity treatment. Recent studies have shown that GLP-1 is a physiological regulator of appetite and food intake. The effect on food intake and satiety is preserved in obese subjects and GLP-1 may therefore have a therapeutic potential. The GLP-1 analogues result in a moderate average weight loss, which is clinically relevant in relation to reducing the risk of type 2 diabetes and cardiovascular disease. Inspired by the hormone profile after gastric bypass, a future strategy in obesity drug development could be to combine several hormones, and thereby produce a superior appetite suppressing hormone profile that may result in a weight loss exceeding that seen in single-agent trials. In conclusion, with the GLP-1 analogues combining a moderate weight loss with beneficial effects on metabolic and cardiovascular risk factors, it seems that we are on the right track for future treatment of obesity.
KW - Animals
KW - Appetite
KW - Bariatric Surgery
KW - Cardiovascular Diseases
KW - Diabetes Mellitus, Type 2
KW - Eating
KW - Glucagon-Like Peptide 1
KW - Humans
KW - Obesity
KW - Risk Factors
KW - Satiation
KW - Weight Loss
U2 - 10.1111/j.1467-789X.2011.00860.x
DO - 10.1111/j.1467-789X.2011.00860.x
M3 - Journal article
C2 - 21401851
VL - 12
SP - 593
EP - 601
JO - Obesity Reviews
JF - Obesity Reviews
SN - 1467-7881
IS - 8
ER -
ID: 38531259